Trial Profile

A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SV 102 (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms LEGION-100
Sponsors Syncromune

Most Recent Events

04 Dec 2025 Results published in the Media Release
04 Nov 2025 According to a Syncromune media release, data from this study featured at the 26th Annual Meeting of the Society of Urological Oncology (SUO).
30 May 2025 According to a Syncromune media release, company announced that the first patient has been successfully dosed in the LEGION-100 trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com